Today’s acute-care learning begins with septic shock resuscitation. Early antibiotics, initial crystalloid and source-control planning remain important, but fluid treatment should not continue as a fixed-volume exercise. After each bolus, clinicians should reassess blood pressure, mental state, capillary refill, urine output, oxygen requirement, lung findings and lactate trajectory. A first litre may be reasonable for many patients, but persistent hypotension with little physiological response should prompt consideration of noradrenaline rather than repeated unresponsive boluses.

Peripheral noradrenaline can allow earlier treatment when local protocols, monitoring and reliable intravenous access are in place. Its use should sit within a broader resuscitation plan that includes repeated perfusion assessment and active review for drainage, debridement or operative source control. Oxygen should also be prescribed to a target rather than maximised automatically, with escalation guided by work of breathing, gas exchange and the reliability of pulse oximetry.

The prehospital trauma evidence reinforces the importance of examining patient-level delay rather than relying only on overall service medians. Advanced procedures can add meaningful scene time even when the median appears unchanged because penetrating trauma and blunt trauma have different time profiles. Before undertaking an intervention, the team should be clear about its expected physiological benefit, likely time cost and whether it supports or delays movement towards haemorrhage control, neurosurgery or theatre.

Post-cardiac arrest oxygen management requires similar attention to timing and context. During the unstable early phase, reliable oxygenation and avoidance of hypoxia take priority. Once monitoring is dependable and the patient is stabilised, inspired oxygen should be reduced towards normoxia. Findings from ventilated intensive-care populations should not be applied mechanically to the first minutes after return of spontaneous circulation.

Necrotising soft tissue infection remains primarily a clinical diagnosis. Severe pain, systemic illness, rapidly progressive swelling, skin change, hypotension or clinical unease should trigger early surgical discussion. Fever, haemorrhagic bullae and fascial gas support the diagnosis when present, but their absence does not exclude it. A low LRINEC score, normal plain radiograph or initially subtle skin findings must not delay escalation. CT can show fascial gas, oedema, enhancement or fluid tracking when the patient is stable enough for imaging, but it should refine rather than postpone surgical decision-making.

The multiple sclerosis update adds a critical-appraisal thread. Across two phase 3 trials, fenebrutinib reduced annualised relapse rate by approximately 51–58% compared with teriflunomide and reduced inflammatory MRI lesion activity by around 75–80%. Disability-progression results were less definitive within the individual trials, although pooled analysis suggested benefit. These efficacy findings need to be considered alongside the imbalance in deaths, infection-associated serious events and reversible liver enzyme elevation.

The practical lesson is to separate relapse, MRI, disability and safety outcomes before reaching an overall judgement about a new disease-modifying therapy. Strong effects on inflammatory activity do not automatically prove long-term patient-centred benefit, and rare serious adverse events remain important even when no single mechanism explains every case. The same caution applies to off-the-shelf large language models in emergency care: fluent answers or strong benchmark results do not replace a broad differential, active testing of alternatives and accountable clinical review.